AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10713874
Drug: Dimenhydrinate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (1 mg kg‐1)
Trial: 10713874
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol (15 micrograms kg‐1) + dimenhydrinate (1 mg kg‐1)
Trial: 10713874
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups compared to placebo
Trial: 7555612
Drug: L-lysine-L-arginine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine-L-arginine combination (lisargin)
Trial: 7335762
Drug: Indobufen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (200 mg b.i.d. by oral route)
Trial: 30794364
Drug: Natural regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural regimen (NR) consisting of a cleanser with natural oils, beeswax, and witch hazel, and day and night creams with natural oils, glycerin, and botanical anti-inflammatories.
Trial: 30794364
Drug: Synthetic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic regimen (CR) consisting of a cetyl alcohol, sodium lauryl sulphate-containing cleanser, and glycerin, polyisobutene-containing lotion.
Trial: 25011730
Drug: computerised CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computerised CBT (cCBT) using OCFighter, an internet-delivered OCD treatment package
Trial: 22362228
Drug: Mesoglycan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan (100 mg/day for 6 months)
Trial: 20976505
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection speed (mean 0.38 ml/s)
Trial: 20976505
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection speed (0.05 ml/s over 40 s)
Trial: 20976505
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection speed
Trial: 20976505
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection speed
Trial: 16774821
Drug: Salbutamol (S,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with volume-controlled (VC) ventilation
Trial: 16774821
Drug: Salbutamol (S,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (S, 100 micro g/puff) administered via metered dose inhaler (MDI) with pressure-support (PS) ventilation
Trial: 12730756
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg daily (Once-a-Week study)
Trial: 15465985
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior treatment of residual symptoms (supplemented by lifestyle modification and well-being therapy)
Trial: 11176319
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days
Trial: 11176319
Drug: Placebo (nonimmunized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (nonimmunized chicken preparation)
Trial: 10626096
Drug: mianserin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 15 mg/d for 3 weeks
Trial: 7589820
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with sulfonylurea or insulin
Trial: 7589820
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy primarily with diet
Trial: 7589820
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with metformin
Trial: 7589820
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy compared with conventional therapy
Trial: 1770147
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n = 33) using transvaginal methotrexate or sulprostone injection
Trial: 23585468
Drug: Cognitive‐behavioral psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral psychotherapy combined with intramuscular (IM) 3‐monthly injections of triptorelin for 12 months (total of 4 injections)
Trial: 23585468
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with cognitive‐behavioral psychotherapy for 12 months (total of 4 injections)
Trial: 18277375
Drug: 1 L/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group A
Trial: 18277375
Drug: 1 L/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group B1
Trial: 18277375
Drug: 1 L/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/d placebo mineral water (Ca:80 mg/L) for Group B2
Trial: 18277375
Drug: 1 L/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L/d high-calcium mineral water (483 mg/L) for Group B2 (after switching from placebo)
Trial: 1468826
Drug: Enalapril 10-20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10-20 mg per day
Trial: 6504945
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg twice daily
Trial: 6504945
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg twice daily
Trial: 6504945
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of pivmecillinam
Trial: 30940355
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration injections
Trial: 27454274
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone 0.5 mg/kg
Trial: 27454274
Drug: Caudal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Caudal dexamethasone 0.1 mg/kg
Trial: 9199122
Drug: Program III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program III - Expanded educational activity and professional cleaning of teeth, sealing, and intensive conservative treatment
Trial: 8293692
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin 75 mg/day (study group, n = 40)
Trial: 23609777
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (daily oral Zn supplements for two months)
Trial: 19543667
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for warmth therapy
Trial: 16936149
Drug: Intravenous C‐peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C‐peptide infusion (dosage 1: 25 pmol . kg(‐1) . min(‐1) bolus followed by 5 pmol . kg(‐1) . min(‐1) continuous infusion; dosage 2: six times higher than dosage 1)
Trial: 16936149
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution (control)
Trial: 15238460
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/d for 12 months
Trial: 11182002
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with vinorelbine, paclitaxel, or gemcitabine plus cisplatin followed by concomitant chemoradiotherapy with the same agents and standard radiation (66 Gy)
Trial: 10221358
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine (CMI) 50-200 mg daily
Trial: 8032080
Drug: 10% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lidocaine spray (Groups A and C)
Trial: 2480941
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600 cGy or 800 cGy
Trial: 2480941
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose therapy
Trial: 4866185
Drug: Pyridoxine 6
RxNorm normalized name: GLYCINE 750MG/NIACIN 25MG/PYRIDOXINE 6MG PWDR,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 6 mg daily
Trial: 4866185
Drug: Pyridoxine 6
RxNorm normalized name: GLYCINE 750MG/NIACIN 25MG/PYRIDOXINE 6MG PWDR,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine 6 mg or 48 mg
Trial: 4866185
Drug: High-dosage isoniazid
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage isoniazid
Trial: 22933750
Drug: Boiled white-fleshed
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule
Trial: 22933750
Drug: Boiled orange-fleshed
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Trial: 22933750
Drug: Fried orange-fleshed
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fried orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Trial: 22933750
Drug: Boiled white-fleshed
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled white-fleshed sweet potatoes (WFSP) and a retinyl palmitate capsule
Trial: 20505660
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg modafinil (divided into three doses)
Trial: 12843214
Drug: SPECT imaging
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT imaging after intravenous injection of hexamethylpropyleneamine oxime or ethylcysteinate dimer
Trial: 2223528
Drug: Diuretic (half-strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (half-strength Moduretic: hydrochlorothiazide 25 mg + amiloride hydrochloride 2.5 mg)
Trial: 2223528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol, hydrochlorothiazide, and amiloride hydrochloride
Trial: 2223528
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (atenolol or diuretic)
Trial: 80275
Drug: Adriamycin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (60 mg/m2 every 3 weeks)
Trial: 80275
Drug: Bleomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (15 mg/m2 weekly)
Trial: 21060109
Drug: IDX184 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 5 mg
Trial: 21060109
Drug: IDX184 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 10 mg
Trial: 21060109
Drug: IDX184 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 25 mg
Trial: 21060109
Drug: IDX184 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg
Trial: 21060109
Drug: IDX184 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 75 mg
Trial: 21060109
Drug: IDX184 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 100 mg
Trial: 19597358
Drug: Self‐Focused Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐Focused Exposure Therapy
Trial: 17313720
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation at 15 mg/d for 6 months
Trial: 17313720
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation at 30 mg/d for 6 months
Trial: 15108100
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B oral suspension
Trial: 15108100
Drug: Nystatin oral
RxNorm normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin oral suspension
Trial: 7861714
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day s.c. of recombinant human growth hormone (rhGH) during the treatment period
Trial: 393464
Drug: fenbufen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenbufen (800 mg/day)
Trial: 23679192
Drug: Toremifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 120 mg (TOR120)
Trial: 23679192
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg (EXE)
Trial: 20952373
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment (e.g., statins)
Trial: 20952373
Drug: Low total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low total cholesterol (<5.5 mmol/l)
Trial: 20952373
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment (statins)
Trial: 16132121
Drug: Antioxidant-supplemented beverage
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant-supplemented beverage (30 ml.kg(‐1) pre-exercise and during exercise)
Trial: 16132121
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 ml.kg(‐1) pre-exercise and during exercise)
Trial: 10434218
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 or 0.2 mg/kg)
Trial: 10434218
Drug: Rocuronium (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.9 or 1.2 mg/kg)
Trial: 7843700
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy for 6 months (3 to 5 million units three times a week)
Trial: 7843700
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy for 6 months (IFN) and 3 additional months (UDCA 10 mg/kg/d)
Trial: 7843700
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy
Trial: 6993163
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy during pregnancy
Trial: 31884472
Drug: T3D-959 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3D-959 (3, 10, 30, or 90 mg daily for 14 days)
Trial: 25758408
Drug: Six 1‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six 1‐h circuit classes targeting balance over a 2‐week period in addition to usual therapy
Trial: 22588577
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral sex therapy
Trial: 22588577
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral sex therapy with ginkgo biloba
Trial: 22588577
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral sex therapy without ginkgo biloba
Trial: 21834061
Drug: MTX in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX in combination with TNF inhibitors
Trial: 21834061
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors as monotherapy
Trial: 21834061
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (SpA patients receiving NSAIDs/analgesics)
Trial: 21834061
Drug: Concomitant prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant prednisolone treatment
Trial: 19726822
Drug: Ionic high‐osmolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic high‐osmolar radiographic contrast agent diatrizoate (Group A)
Trial: 19726822
Drug: Non‐ionic iso‐osmolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐ionic iso‐osmolar contrast agent iodixanol (Group B)
Trial: 17461857
Drug: Alovudine 2
RxNorm normalized name: Alovudine
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alovudine 2 mg/day
Trial: 17461857
Drug: Alovudine 1
RxNorm normalized name: Alovudine
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alovudine 1 mg/day
Trial: 11269571
Drug: RG 12525
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12525 100 mg qd for 4 days
Trial: 11269571
Drug: RG 12525
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12525 600 mg qd for 4 days
Trial: 7958164
Drug: buserelin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buserelin (1.2 mg/day, intranasally for 3 months)
Trial: 2885599
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg daily for the first week, tapering off over 2 weeks)
Trial: 28497396
Drug: Progressive Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive Muscle Relaxation Training (PMRT) plus Chinese Medicine Five-Element Music Therapy
Trial: 21208550
Drug: AS03(A)-adjuvanted split
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted split H1N1 vaccine
Trial: 21208550
Drug: Whole-virion (WV)
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virion (WV) vaccine
Trial: 16157857
Drug: Combination brace
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination brace and physical therapy
Trial: 11955605
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant children
Trial: 9917226
Drug: L-754,030 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-754,030 (400 mg before cisplatin and 300 mg on days 2 to 5)
Trial: 9917226
Drug: L-754,030 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-754,030 (400 mg before cisplatin and placebo on days 2 to 5)
Trial: 1962596
Drug: Droloxifene 20
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 20 mg once a day
Trial: 1962596
Drug: Droloxifene 40
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 40 mg once a day
Trial: 1962596
Drug: Droloxifene 80
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 80 mg once a day
Trial: 1962596
Drug: Droloxifene 120
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 120 mg once a day (pilot study)
Trial: 7060371
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg norethisterone (NET) minipill
Trial: 7060371
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg of ethinylestradiol for 7 days
Trial: 30396772
Drug: Iso-osmolar oral
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso-osmolar oral supplement (279 mOsm/kg)
Trial: 30396772
Drug: Hyperosmolar oral
RxNorm normalized name: HYPEROSMOTIC LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar oral supplement (681 mOsm/kg)
Trial: 28235537
Drug: Desflurane 4.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane 4.1% with remifentanil 1ng/ml (R1 group)
Trial: 28235537
Drug: Desflurane 3.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane 3.4% with remifentanil 3ng/ml (R3 group)
Trial: 28235537
Drug: R1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1 group (1ng/ml of remifentanil)